The U.S. Food and Drug Administration on Tuesday said it plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under age 65, effectively limiting them to older adults and those at risk of developing severe illness.

The US Food and Drug Administration (FDA) announces new regulatory guidelines for future COVID-19 vaccines and booster shots. Moderna (MRNA) and Pfizer (PFE) shares move higher on this news, while Novavax (NVAX) takes a dip.

FDA Commissioner Marty Makary and top U.S. vaccines regulator Vinay Prasad said based on data from tests that measure immune response in patients, they anticipate that the FDA will be able to approve the boosters for adults over the age of 65 years.

Shares of Moderna surged to lead S&P 500 gainers Tuesday after the Food and Drug Administration issued new guidance for COVID-19 vaccine boosters.

Moderna’s combined Covid and flu shot outperformed the existing standalone vaccines for both viruses, according to the results of a phase 3 clinical trial published Wednesday in the Journal of the American Medical Association.

The stock might be down substantially over the past three years, but it isn't out of the picture yet. Teladoc Health is a telemedicine specialist that rose in popularity in 2020 and 2021, when people were stuck at home and forced to turn to telehealth for medical attention.

Covid vaccine manufacturer Moderna has completed a new site in the UK, which it says will help prepare the the country against future pandemics. The Moderna Innovation and Technology Centre (MITC) in Harwell, Oxfordshire, is now fully operational and has its manufacturer's license by the Medicines and Healthcare products Regulatory Agency.